Vestibular schwannomas are histopathologically benign tumors arising from the Schwann cell sheath surrounding the vestibular branch of cranial nerve VIII and are related to the NF2 gene and its product merlin. Merlin acts as a tumor suppressor and as a mediator of contact inhibition. Thus, deficiencies in both NF2 genes lead to vestibular schwannoma development. Recently, there have been major advances in our knowledge of the molecular biology of vestibular schwannomas as well as the development of novel therapies for its treatment. In this article the authors comprehensively review the recent advances in the molecular biology and characterization of vestibular schwannomas as well as the development of modern treatments for vestibular schwannoma. For instance, merlin is involved with a number of receptors including the CD44 receptor, EGFR, and signaling pathways, such as the Ras/raf pathway and the canonical Wnt pathway. Recently, merlin was also shown to interact in the nucleus with E3 ubiquitin ligase CRL4DCAF1. A greater understanding of the molecular mechanisms behind vestibular schwannoma tumorigenesis has begun to yield novel therapies. Some authors have shown that Avastin induces regression of progressive schwannomas by over 40% and improves hearing. An inhibitor of VEGF synthesis, PTC299, is currently in Phase II trials as a potential agent to treat vestibular schwannoma. Furthermore, in vitro studies have shown that trastuzumab (an ERBB2 inhibitor) reduces vestibular schwannoma cell proliferation. With further research it may be possible to significantly reduce morbidity and mortality rates by decreasing tumor burden, tumor volume, hearing loss, and cranial nerve deficits seen in vestibular schwannomas.
Abbreviations used in this paper: NF1 = neurofibromatosis Type 1; NF2 = NF Type 2.
Address correspondence to: Isaac Yang, M.D., Department of Neurological Surgery, University of California, Los Angeles, 695 Charles E. Young Drive South, Gonda 3357, Los Angeles, California 90095-1761. email: firstname.lastname@example.org.
Please include this information when citing this paper: published online July 29, 2011; DOI: 10.3171/2011.6.JNS11131.
BariMEForsterDMKemenyAAWaltonLHardyDAndersonJR: Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literature. Br J Neurosurg16:284–2892002
ClarkJJProvenzanoMDiggelmannHRXuNHansenSSHansenMR: The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol29:846–8532008
EvansDGBirchJMRamsdenRTSharifSBaserME: Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet43:289–2942006
EvansDGHusonSMDonnaiDNearyWBlairVTeareD: A genetic study of type 2 neurofibromatosis in the United Kingdom. I Prevalance, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet29:841–8461992
GiovanniniMRobanus-MaandagEvan der ValkMNiwa-KawakitaMAbramowskiVGoutebrozeL: Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev14:1617–16302000
HadfieldKDSmithMJUrquhartJEWallaceAJBowersNLKingAT: Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene29:6216–62212010
JääskeläinenJPaetauAPyykköIBlomstedtGPalvaTTrouppH: Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. J Neurosurg80:541–5471994
JamesMFManchandaNGonzalez-AgostiCHartwigJHRameshV: The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem J356:377–3862001
JohnsonJRCohenMSridharaRChenYFWilliamsGMDuanJ: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res11:6414–64212005
LeeDJWestraWHStaeckerHLongDNiparkoJKSlatteryWHIII: Clinical and histopathologic features of recurrent vestibular schwannoma (acoustic neuroma) after stereotactic radiosurgery. Otol Neurotol24:650–6602003
McCallCMMiliani de MarvalPLChastainPDIIJacksonSCHeYJKotakeY: Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development. Mol Cell Biol28:5621–56332008
MooreMJGoldsteinDHammJFigerAHechtJRGallingerS: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol25:1960–19662007
SainioMZhaoFHeiskaLTurunenOden BakkerMZwarthoffE: Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci110:2249–22601997
TakahashiKSasakiTMammotoATakaishiKKameyamaTTsukitaS: Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J Biol Chem272:23371–233751997